The Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemias
Zachary J Faber,Xiang Chen,Amanda Larson Gedman,Kristy Boggs,Jinjun Cheng,Jing Ma,Ina Radtke,Jyh-Rong Chao,Michael P Walsh,Guangchun Song,Anna K Andersson,Jinjun Dang,Li Dong,Yu Liu,Robert Huether,Zhongling Cai,Heather Mulder,Gang Wu,Michael Edmonson,Michael Rusch,Chunxu Qu,Yongjin Li,Bhavin Vadodaria,Jianmin Wang,Erin Hedlund,Xueyuan Cao,Donald Yergeau,Joy Nakitandwe,Stanley B Pounds,Sheila Shurtleff,Robert S Fulton,Lucinda L Fulton,John Easton,Evan Parganas,Ching-Hon Pui,Jeffrey E Rubnitz,Li Ding,Elaine R Mardis,Richard K Wilson,Tanja A Gruber,Charles G Mullighan,Richard F Schlenk,Peter Paschka,Konstanze Döhner,Hartmut Döhner,Lars Bullinger,Jinghui Zhang,Jeffery M Klco,James R Downing
DOI: https://doi.org/10.1038/ng.3709
IF: 30.8
2016-01-01
Nature Genetics
Abstract:Lars Bullinger, Jinghui Zhang, Jeffery Klco, James Downing and colleagues report a detailed genomic analysis of pediatric and adult core-binding factor acute myeloid leukemias (CBF-AMLs). They identify recurrent mutations in CCND2, MGA, DHX15 and ZBTB7A and highlight dramatic differences in the landscape of cooperating mutations between different CBF-AML subtypes. Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements involving the core-binding factor (CBF) transcriptional complex. To better understand the genomic landscape of CBF-AMLs, we analyzed both pediatric (n = 87) and adult (n = 78) samples, including cases with RUNX1-RUNX1T1 (n = 85) or CBFB-MYH11 (n = 80) rearrangements, by whole-genome or whole-exome sequencing. In addition to known mutations in the Ras pathway, we identified recurrent stabilizing mutations in CCND2, suggesting a previously unappreciated cooperating pathway in CBF-AML. Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex. This detailed analysis provides insights into the pathogenesis and development of CBF-AML, while highlighting dramatic differences in the landscapes of cooperating mutations for these related AML subtypes.